the future of

PolyActiva is focused

on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.


The versatile Prezia Sustained Drug Delivery Technology platform is based on extensive scientific research that has resulted in the creation of a unique method for precise and controlled drug delivery.


PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

The interim Phase 2a results demonstrate a sustained >20% reduction of IOP after 6 months with a favorable safety profile.

PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting – March 2022

Contact Us

For more information on PolyActiva, please complete the form below: